000			03552nam a22006497a 4500
008			180928s20192019 xxu||||| |||| 00| 0 eng d
022			_a1354-523X
024			_a10.1111/odi.12969 [doi]
040			_aOvid MEDLINE(R)
099			_a30169900
245			_aPoor patient compliance with instructions for continuous sialogogues after <sup>131</sup> I therapy.
251			_aOral Diseases. 25(1):158-163, 2019 Jan.
252			_aOral Dis. 25(1):158-163, 2019 Jan.
253			_aOral diseases
260			_c2019
260			_fFY2019
265			_saheadofprint
265			_sppublish
266			_d2018-09-28
520			_aCONCLUSION: Despite repetitive instructions to use sialogogues continuously, most patients (90%) were not compliant. In future studies, strict monitoring and evaluation of patient compliance will be crucial when assessing the effect of continuous versus intermittent or delayed initiation of sialogogues.
520			_aCopyright (c) 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. All rights reserved.
520			_aMETHODS: Differentiated thyroid cancer patients who were clinically scheduled for an <sup>131</sup> I therapy at MedStar Washington Hospital Center between 2012 and 2013 were given instructions for continuous sialogogues per standard clinical protocol. The prospective survey was given at multiple time points.
520			_aOBJECTIVES: To analyze the role of patient compliance as a factor in evaluating the effectiveness of continuous sialogogues to prevent salivary side effects from <sup>131</sup> I therapy in differentiated thyroid cancer patients.
520			_aRESULTS: Ninety-nine patients consented to participate of whom 94 participants had complete data. The mean prescribed <sup>131</sup> I activity was 121 +/- 50 mCi (4.5 +/- 1.9 GBq), range 27.5-288 mCi (1.0-10.7 GBq ). Overall, only 10% (9/94) of patients were compliant with continuous sialogogues. Even though all patients took sialogogues on the first day of post-therapy, 17% of participants did not continuously take sialogogues during the first day, 60% during the first night, and 72% on the second day despite rigorous instructions to continue for two days.
546			_aEnglish
650			_a*Medication Adherence
650			_a*Salivation/de [Drug Effects]
650			_a*Sialadenitis/dt [Drug Therapy]
650			_a*Thyroid Neoplasms/rt [Radiotherapy]
650			_a*Xerostomia/dt [Drug Therapy]
650			_aAdult
650			_aAged
650			_aFemale
650			_aHumans
650			_aIodine Radioisotopes/tu [Therapeutic Use]
650			_aMale
650			_aMiddle Aged
650			_aProspective Studies
650			_aSialadenitis/et [Etiology]
650			_aSurveys and Questionnaires
650			_aThyroid Neoplasms/co [Complications]
650			_aXerostomia/et [Etiology]
651			_aMedStar Washington Hospital Center
656			_aMedicine/Endocrinology
656			_aMedicine/Nuclear Medicine
657			_aJournal Article
700			_aBurman, Kenneth D
700			_aKulkarni, Kanchan
700			_aMoreau, Shari
700			_aVan Nostrand, Douglas
700			_aWartofsky, Leonard
700			_aWu, Di
790			_aBurman KD, Kharazi P, Khorjekar G, Kulkarni K, Moreau S, Van Nostrand D, Wartofsky L, Wu D
856			_uhttps://dx.doi.org/10.1111/odi.12969 _zhttps://dx.doi.org/10.1111/odi.12969
858			_yWu, Di _uhttp://orcid.org/0000-0003-1567-1977 _zhttp://orcid.org/0000-0003-1567-1977
942			_cART _dArticle
999			_c11101 _d11101